Navigation Links
Neurobiological Technologies Sets Date for First Quarter Financial Results
Date:11/4/2008

EMERYVILLE, Calif., Nov. 4 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced it will release its first quarter 2009 financial results, for the quarter ended September 30, 2008, and host a conference call on November 6, 2008.

Hosting the call will be Paul E. Freiman, President and Chief Executive Officer, and Matthew M. Loar, Vice President and Chief Financial Officer. The details for the call are as follows:

Live Call:

-- Date: Thursday, November 6, 2007

-- Time: 10:30 a.m. ET, 9:30 a.m. CT, 7:30 a.m. PT

-- Dial-in number: 800-309-1245 (U.S.) 719-457-2080 (International)

Webcast of Call:

-- A live webcast can be accessed online by going to:

http://investor.shareholder.com/ntii/events.cfm

Telephonic Replay: (Archived for 90 days)

A playback of the conference call will be available from 1:30 PM November

6 (ET) through midnight November 13 (ET).

Replay number: 888-203-1112 (U.S. and Canada) / 719-457-0820

(international).

Replay access code: 8094663.

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc., (Nasdaq: NTII) is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug for the treatment of acute ischemic stroke. Viprinex has multiple mechanisms of action and is specifically designed to extend the time period that patients can be treated after the onset of a stroke. Acute ischemic stroke is one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options. NTI also has early-stage development programs for Alzheimer's and Huntington's diseases and rights to receive payments on an approved drug for Alzheimer's disease and an investigational drug in Phase 3 trials for brain swelling.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neurobiological Technologies Reports Receipt of $2 Million Royalty Payment for Quarterly Sales of Memantine
2. Neurobiological Technologies to Present at the BIO Investor Forum in San Francisco on October 30, 2008
3. Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program
4. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q4/08 Review Issued by Scimitar Equity, LLC
5. Neurobiological Technologies Announces Dates for 2008 Fiscal Year End Financial Results Conference Call and Presentation at MCF Investor Summit
6. Neurobiological Technologies Reports Receipt of $2.1 Million Royalty Payment for Quarterly Sales of Memantine
7. Neurobiological Technologies CEO to Retire on December 31, 2008
8. Neurobiological Technologies Reports Third Quarter Financial Results
9. Neurobiological Technologies Sets Date for Third Quarter Financial Results
10. Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
11. Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Charlotte, N.C. (PRWEB) , ... October 11, 2017 ... ... ARCS® Foundation President Andi Purple announced Dr. Suneel I. Sheikh, the ... Laboratories ( ASTER Labs ), Inc. has been selected for membership in ...
(Date:10/11/2017)... ... ... Personal eye wash is a basic first aid supply for any work environment, but most ... you rinse first if a dangerous substance enters both eyes? It’s one less decision, and ... unique dual eye piece. , “Whether its dirt and debris, or an acid or alkali, ...
(Date:10/11/2017)... ... 11, 2017 , ... Proscia Inc ., a data ... titled, “Pathology is going digital. Is your lab ready?” with Dr. Nicolas Cacciabeve, ... and how Proscia improves lab economics and realizes an increase in diagnostic confidence.* ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , ... of Cancer Research, London (ICR) and ... with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple ... as MUK nine . The University of ... is partly funded by Myeloma UK, and ICR will perform ...
Breaking Biology Technology:
(Date:6/14/2017)... 15, 2017  IBM (NYSE: IBM ) is introducing several ... dedicated to developing collaboration between startups and global businesses, taking ... During the event, nine startups will showcase the solutions they ... industries. France is ... with a 30 percent increase in the number of startups ...
(Date:5/16/2017)... DALLAS , May 16, 2017   ... for health organizations, and MD EMR Systems ... certified development partner for GE, have established a ... Patient Portal product and the GE Centricity™ products, ... Centricity EMR. These new integrations ...
(Date:4/19/2017)... , April 19, 2017 ... its vendor landscape is marked by the presence of ... is however held by five major players - 3M ... these companies accounted for nearly 61% of the global ... leading companies in the global military biometrics market boast ...
Breaking Biology News(10 mins):